IMpassion130 [137], the first randomized controlled study in first-line therapy in unresected metastatic TNBC, showed a significant prolonged progression-free survival in patients receiving combination nab-paclitaxel and atezolizumab (anti PD-L1) compared with nab-paclitaxel alone, the strongest effect in patients in tumours with >1% staining of immune cells (ICs)(PD-L1 positive). Here, CD274 is linked to neoplasm.